We calculated the CHOKAI and STONE scores of each patient based on the physical and laboratory findings. The primary outcome was the area under the curve (AUC) differences with receiver operating characteristic curve in each model. The secondary outcome was to determine an optimal cut-off score and the diagnostic accuracy of each model in Japan.
INTRODUCTION AND OBJECTIVES:
Patients are living longer with an increasing number of co-morbidities. Minimally invasive ureterorenoscopy (URS) to manage calculi or transitional cell carcinoma can be performed on a day-case basis under general or spinal anaesthesia, however certain co-morbid patients are not suitable for this and require a different approach. We report on URS under local anaesthesia (LA) using intra-ureteric bupivacaine as the primary form of anaesthesia METHODS: A retrospective analysis over 6 years at a single centre was undertaken on all patients who underwent URS under LA. Patients were placed in the lithotomy position and prepared and draped as for cystoscopy. Intra-urethral 2% lidocaine gel was instilled prior to cystoscopy. A guidewire followed by a dual lumen catheter were inserted into the ureter and bupivicaine 0.5% was infused under pressure. After 2 minutes, an access sheath was inserted and URS performed with stone fragmentation using a Holmium: YAG laser. Procedural time was generally limited to one hour as the surgeon's preference for ureteroscopy.
RESULTS: Twelve patients had a total of 42 procedures under LA. Stone size varied from 4-35mm. Seventy-one percent of procedures (30/42) did not require any sedation or intravenous analgesia as an adjunct to the bupivacaine. No procedures were abandoned and there were no conversions to general/spinal anaesthesia. Eighty-one percent of cases (34/42) were performed as day-case or overnight stays. There were no complications secondary to the use of LA and the complication rate overall was similar to that for conventional anaesthesia.
CONCLUSIONS: This study highlights that URS can be safely performed under LA. It is well tolerated and represents an option for a carefully selected cohort patients who have been adequately counselled, and who would be at high risk from conventional anaesthesia due to cardiovascular or respiratory co-morbidities. Such patients may otherwise be considered 00 unfit 00 for endourological intervention under conventional anaesthesia.
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PD12-08 STENT DURATION AND INCREASED PAIN IN THE HOURS AFTER URETERAL STENT REMOVAL
Michael Rezaee*, Annah Vollstedt, Vernon Pais, Lebanon, NH INTRODUCTION AND OBJECTIVES: Causes of pain after ureteral stent removal are poorly understood. Stent duration may be a factor. We studied the relationship between pain after ureteral stent removal and patient and procedural factors.
METHODS: A survey to assess the relationship between quality of life and subsequent treatment decisions was randomly distributed to patients greater than or equal to 18 years of age and with a history of a ureteral stent in seven medical centers across the U.S. participating in an endourology research collaborative between July 2016 and June 2018. Statistical analyses were performed using Chi-square and multiple logistic regression.
RESULTS: A total of 327 completed surveys were analyzed. Twenty seven percent of patients reported increased pain in the hours after ureteral stent removal. Patients with a stent 7 days or less were significantly more likely to experience pain after stent removal compared to those with a stent more than 7 days (33.3% vs. 22.8%, p[0.04). After adjusting for age, gender, and health status, patients Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e223
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